Claudication rarely takes a limb. But in patients over 80, the attempt to treat it surgically may take something just as important. New data, presented at VAM 2026 by Jeffrey Siracuse, MD, makes the case that for octogenarians with intermittent claudication, the risks of invasive revascularization routinely exceed its benefits.
The clinical tension at the center of the presentation is not new, but the scale of data supporting it is. Managing claudication in octogenarians has long required balancing symptom relief against procedural risk and that balance has historically been difficult to assess without large-scale outcomes data specific to this age group. Siracuse’s analysis used registry data to examine exactly that question, with findings that raise serious concerns about how frequently the surgical option is being chosen.
“Interventions for claudication in the elderly are high-risk with often diminishing returns,” said Siracuse, professor and chief of the Division of Vascular and Endovascular Surgery at Boston University. “Preserving mobility with conservative management should be balanced with risk for intervention.”
The data show that octogenarians face significantly higher 30-day mortality rates and increased access-site complications compared with younger patient cohorts. One year after an intervention, elderly patients demonstrate a markedly lower likelihood of remaining independently ambulatory, a finding that strikes at the core of what surgical treatment for claudication is supposed to achieve. If the goal is preserving functional independence, a procedure that undermines it fails on its own terms.
“We need to judge procedural success by durability and improved functional status, not just a patent vessel,” said Siracuse. “Teams must engage in robust shared decision-making with patients, transparently weighing marginal symptom relief against the very real risks of permanent functional decline and perioperative complications.”
Beyond the outcomes data, the presentation also highlights a procedural timing concern that many elderly patients are undergoing invasive intervention before exhausting noninvasive options. Supervised exercise therapy and optimal medical management remain underutilized in this population, yet both carry substantially lower risk profiles than surgery and have established efficacy in improving claudication symptoms and walking performance.
“For older patients, surgery should be a last resort rather than a first-line treatment,” said Siracuse. “Claudication rarely leads to limb loss and the risk of complications makes conservative management the safest standard of care in most cases.”
The Society for Vascular Surgery (SVS) has published criteria specifically addressing when surgical intervention is warranted in claudication patients and Siracuse frames adherence to those guidelines as both a clinical and ethical obligation. Treating a patient who has not yet attempted supervised exercise or optimized medical therapy represents a missed opportunity to achieve symptom relief without exposing an elderly patient to the mortality and complication risks that registry data now quantify.
“Surgeons should follow the SVS criteria and reserve surgery only for those who have failed conservative management and are likely to benefit,” said Siracuse.
Siracuse said comparative studies focused specifically on frail elderly patients that measure supervised exercise against intervention on functional outcomes, not simply vessel patency, are needed. He also pointed to the rise of outpatient procedure centers as an area warranting scrutiny, noting that research should examine whether that setting is contributing to a higher frequency of procedures in patients who might be better served by conservative care first.
The broader message, Siracuse says, is one of recalibration — not an argument against surgery, but a call to apply it where evidence supports genuine benefit rather than where it’s technically possible.
“Care should be individualized,” said Siracuse. “The goal is durable functional improvement and preserved independence, not a patent vessel, and achieving that requires honest conversations with patients about what the data actually show for their age group.”
